Chronic Myeloid Leukemia /Features

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

Chronic Myeloid Leukemia
5 years
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals